Does the media prefer BDX or PODD?

In the previous week, Becton, Dickinson and Company had 6 more articles in the media than Insulet. MarketBeat recorded 20 mentions for Becton, Dickinson and Company and 14 mentions for Insulet. Becton, Dickinson and Company's average media sentiment score of 1.42 beat Insulet's score of 1.09 indicating that Becton, Dickinson and Company is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Becton, Dickinson and Company 17 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Insulet 10 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, DXCM or PODD?

DexCom has higher revenue and earnings than Insulet. DexCom is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DexCom $4.66B 5.70 $836.30M $2.34 29.43 Insulet $2.71B 3.69 $247.10M $4.30 33.53

Is DXCM or PODD more profitable?

DexCom has a net margin of 19.31% compared to Insulet's net margin of 10.44%. DexCom's return on equity of 33.33% beat Insulet's return on equity. Company Net Margins Return on Equity Return on Assets DexCom 19.31% 33.33% 13.19% Insulet 10.44% 26.87% 12.01%

Does the media prefer DXCM or PODD?

In the previous week, DexCom had 14 more articles in the media than Insulet. MarketBeat recorded 28 mentions for DexCom and 14 mentions for Insulet. Insulet's average media sentiment score of 1.09 beat DexCom's score of 1.03 indicating that Insulet is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DexCom 18 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Insulet 10 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, RMD or PODD?

ResMed has higher revenue and earnings than Insulet. ResMed is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ResMed $5.15B 5.37 $1.40B $10.37 18.37 Insulet $2.71B 3.69 $247.10M $4.30 33.53

Is RMD or PODD more profitable?

ResMed has a net margin of 27.44% compared to Insulet's net margin of 10.44%. Insulet's return on equity of 26.87% beat ResMed's return on equity. Company Net Margins Return on Equity Return on Assets ResMed 27.44% 25.35% 18.69% Insulet 10.44% 26.87% 12.01%

Does the media refer more to RMD or PODD?

In the previous week, Insulet had 2 more articles in the media than ResMed. MarketBeat recorded 14 mentions for Insulet and 12 mentions for ResMed. Insulet's average media sentiment score of 1.09 beat ResMed's score of 0.82 indicating that Insulet is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ResMed 6 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Insulet 10 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, STE or PODD?

STERIS has higher revenue and earnings than Insulet. STERIS is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio STERIS $5.94B 3.31 $782.30M $7.93 25.45 Insulet $2.71B 3.69 $247.10M $4.30 33.53

Is STE or PODD more profitable?

STERIS has a net margin of 13.18% compared to Insulet's net margin of 10.44%. Insulet's return on equity of 26.87% beat STERIS's return on equity. Company Net Margins Return on Equity Return on Assets STERIS 13.18% 14.15% 9.52% Insulet 10.44% 26.87% 12.01%

Does the media refer more to STE or PODD?

In the previous week, Insulet had 7 more articles in the media than STERIS. MarketBeat recorded 14 mentions for Insulet and 7 mentions for STERIS. Insulet's average media sentiment score of 1.09 beat STERIS's score of 1.00 indicating that Insulet is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment STERIS 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Insulet 10 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, PODD or GMED?

Globus Medical has higher revenue and earnings than Insulet. Globus Medical is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insulet $2.71B 3.69 $247.10M $4.30 33.53 Globus Medical $3.10B 3.49 $537.87M $4.30 18.54

Is PODD or GMED more profitable?

Globus Medical has a net margin of 18.92% compared to Insulet's net margin of 10.44%. Insulet's return on equity of 26.87% beat Globus Medical's return on equity. Company Net Margins Return on Equity Return on Assets Insulet 10.44% 26.87% 12.01% Globus Medical 18.92% 13.46% 11.65%

Does the media favor PODD or GMED?

In the previous week, Insulet and Insulet both had 14 articles in the media. Insulet's average media sentiment score of 1.09 beat Globus Medical's score of 0.81 indicating that Insulet is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insulet 10 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Globus Medical 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Insulet (PODD) Competitors

$144.20 +5.23 (+3.76%)

As of 02:27 PM Eastern

Compare

PODD vs. BDX, DXCM, RMD, STE, and GMED

Should you buy Insulet stock or one of its competitors? MarketBeat compares Insulet with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Insulet include Becton, Dickinson and Company (BDX), DexCom (DXCM), ResMed (RMD), STERIS (STE), and Globus Medical (GMED). These companies are all part of the "health care equipment" industry.

How does Insulet compare to Becton, Dickinson and Company?

Becton, Dickinson and Company (NYSE:BDX) and Insulet (NASDAQ:PODD) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

Becton, Dickinson and Company has higher revenue and earnings than Insulet. Insulet is trading at a lower price-to-earnings ratio than Becton, Dickinson and Company, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Becton, Dickinson and Company	$21.84B	1.83	$1.68B	$3.95	36.68
Insulet	$2.71B	3.69	$247.10M	$4.30	33.53

In the previous week, Becton, Dickinson and Company had 6 more articles in the media than Insulet. MarketBeat recorded 20 mentions for Becton, Dickinson and Company and 14 mentions for Insulet. Becton, Dickinson and Company's average media sentiment score of 1.42 beat Insulet's score of 1.09 indicating that Becton, Dickinson and Company is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Becton, Dickinson and Company	17 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insulet	10 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Becton, Dickinson and Company has a beta of 0.22, meaning that its stock price is 78% less volatile than the broader market. Comparatively, Insulet has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market.

Insulet has a net margin of 10.44% compared to Becton, Dickinson and Company's net margin of 5.33%. Insulet's return on equity of 26.87% beat Becton, Dickinson and Company's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Becton, Dickinson and Company	5.33%	15.37%	7.11%
Insulet	10.44%	26.87%	12.01%

87.0% of Becton, Dickinson and Company shares are owned by institutional investors. 0.4% of Becton, Dickinson and Company shares are owned by insiders. Comparatively, 0.4% of Insulet shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Becton, Dickinson and Company currently has a consensus price target of $181.00, indicating a potential upside of 24.94%. Insulet has a consensus price target of $238.67, indicating a potential upside of 65.51%. Given Insulet's stronger consensus rating and higher probable upside, analysts plainly believe Insulet is more favorable than Becton, Dickinson and Company.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Becton, Dickinson and Company	1 Sell rating(s)	8 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.38
Insulet	1 Sell rating(s)	5 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Insulet beats Becton, Dickinson and Company on 9 of the 16 factors compared between the two stocks.

How does Insulet compare to DexCom?

DexCom (NASDAQ:DXCM) and Insulet (NASDAQ:PODD) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

In the previous week, DexCom had 14 more articles in the media than Insulet. MarketBeat recorded 28 mentions for DexCom and 14 mentions for Insulet. Insulet's average media sentiment score of 1.09 beat DexCom's score of 1.03 indicating that Insulet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DexCom	18 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Insulet	10 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

DexCom has higher revenue and earnings than Insulet. DexCom is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DexCom	$4.66B	5.70	$836.30M	$2.34	29.43
Insulet	$2.71B	3.69	$247.10M	$4.30	33.53

DexCom has a beta of 1.45, indicating that its share price is 45% more volatile than the broader market. Comparatively, Insulet has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market.

97.8% of DexCom shares are owned by institutional investors. 0.3% of DexCom shares are owned by insiders. Comparatively, 0.4% of Insulet shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

DexCom presently has a consensus target price of $84.88, suggesting a potential upside of 23.25%. Insulet has a consensus target price of $238.67, suggesting a potential upside of 65.51%. Given Insulet's higher possible upside, analysts plainly believe Insulet is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DexCom	1 Sell rating(s)	3 Hold rating(s)	21 Buy rating(s)	2 Strong Buy rating(s)	2.89
Insulet	1 Sell rating(s)	5 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.75

DexCom has a net margin of 19.31% compared to Insulet's net margin of 10.44%. DexCom's return on equity of 33.33% beat Insulet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DexCom	19.31%	33.33%	13.19%
Insulet	10.44%	26.87%	12.01%

Summary

DexCom beats Insulet on 11 of the 17 factors compared between the two stocks.

How does Insulet compare to ResMed?

ResMed (NYSE:RMD) and Insulet (NASDAQ:PODD) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

ResMed has higher revenue and earnings than Insulet. ResMed is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ResMed	$5.15B	5.37	$1.40B	$10.37	18.37
Insulet	$2.71B	3.69	$247.10M	$4.30	33.53

55.0% of ResMed shares are owned by institutional investors. 0.7% of ResMed shares are owned by insiders. Comparatively, 0.4% of Insulet shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

ResMed has a net margin of 27.44% compared to Insulet's net margin of 10.44%. Insulet's return on equity of 26.87% beat ResMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ResMed	27.44%	25.35%	18.69%
Insulet	10.44%	26.87%	12.01%

ResMed presently has a consensus price target of $270.82, indicating a potential upside of 42.18%. Insulet has a consensus price target of $238.67, indicating a potential upside of 65.51%. Given Insulet's stronger consensus rating and higher possible upside, analysts plainly believe Insulet is more favorable than ResMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ResMed	0 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.67
Insulet	1 Sell rating(s)	5 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.75

ResMed has a beta of 0.8, suggesting that its share price is 20% less volatile than the broader market. Comparatively, Insulet has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market.

In the previous week, Insulet had 2 more articles in the media than ResMed. MarketBeat recorded 14 mentions for Insulet and 12 mentions for ResMed. Insulet's average media sentiment score of 1.09 beat ResMed's score of 0.82 indicating that Insulet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ResMed	6 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insulet	10 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

ResMed beats Insulet on 9 of the 17 factors compared between the two stocks.

How does Insulet compare to STERIS?

STERIS (NYSE:STE) and Insulet (NASDAQ:PODD) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations and dividends.

STERIS currently has a consensus price target of $278.00, indicating a potential upside of 37.76%. Insulet has a consensus price target of $238.67, indicating a potential upside of 65.51%. Given Insulet's higher possible upside, analysts plainly believe Insulet is more favorable than STERIS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
STERIS	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Insulet	1 Sell rating(s)	5 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.75

STERIS has a net margin of 13.18% compared to Insulet's net margin of 10.44%. Insulet's return on equity of 26.87% beat STERIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
STERIS	13.18%	14.15%	9.52%
Insulet	10.44%	26.87%	12.01%

94.7% of STERIS shares are held by institutional investors. 1.1% of STERIS shares are held by insiders. Comparatively, 0.4% of Insulet shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Insulet had 7 more articles in the media than STERIS. MarketBeat recorded 14 mentions for Insulet and 7 mentions for STERIS. Insulet's average media sentiment score of 1.09 beat STERIS's score of 1.00 indicating that Insulet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
STERIS	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insulet	10 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

STERIS has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market. Comparatively, Insulet has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market.

STERIS has higher revenue and earnings than Insulet. STERIS is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
STERIS	$5.94B	3.31	$782.30M	$7.93	25.45
Insulet	$2.71B	3.69	$247.10M	$4.30	33.53

Summary

Insulet beats STERIS on 9 of the 15 factors compared between the two stocks.

How does Insulet compare to Globus Medical?

Insulet (NASDAQ:PODD) and Globus Medical (NYSE:GMED) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

In the previous week, Insulet and Insulet both had 14 articles in the media. Insulet's average media sentiment score of 1.09 beat Globus Medical's score of 0.81 indicating that Insulet is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insulet	10 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Globus Medical	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Globus Medical has higher revenue and earnings than Insulet. Globus Medical is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insulet	$2.71B	3.69	$247.10M	$4.30	33.53
Globus Medical	$3.10B	3.49	$537.87M	$4.30	18.54

Insulet presently has a consensus price target of $238.67, indicating a potential upside of 65.51%. Globus Medical has a consensus price target of $105.00, indicating a potential upside of 31.68%. Given Insulet's higher probable upside, research analysts plainly believe Insulet is more favorable than Globus Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insulet	1 Sell rating(s)	5 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.75
Globus Medical	0 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.87

95.2% of Globus Medical shares are owned by institutional investors. 0.4% of Insulet shares are owned by company insiders. Comparatively, 18.4% of Globus Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Globus Medical has a net margin of 18.92% compared to Insulet's net margin of 10.44%. Insulet's return on equity of 26.87% beat Globus Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insulet	10.44%	26.87%	12.01%
Globus Medical	18.92%	13.46%	11.65%

Insulet has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market. Comparatively, Globus Medical has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market.

Summary

Insulet beats Globus Medical on 8 of the 15 factors compared between the two stocks.

Get Insulet News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PODD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PODD vs. The Competition

Export

Metric	Insulet	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$9.99B	$8.13B	$6.49B	$12.17B
Dividend Yield	N/A	2.55%	2.68%	5.81%
P/E Ratio	33.53	15.24	24.68	24.05
Price / Sales	3.69	5.54	530.15	111.08
Price / Cash	23.05	17.32	27.92	37.84
Price / Book	6.69	3.24	10.87	6.56
Net Income	$247.10M	$226.25M	$3.56B	$336.88M
7 Day Performance	-2.36%	-3.13%	1.99%	0.06%
1 Month Performance	-6.89%	-3.19%	0.74%	1.07%
1 Year Performance	-53.13%	2.28%	33.47%	32.09%

Insulet Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PODD Insulet	4.6557 of 5 stars	$144.20 +3.8%	$238.67 +65.5%	-54.2%	$9.99B	$2.71B	33.53	5,400	Positive News Analyst Forecast Gap Up
BDX Becton, Dickinson and Company	4.938 of 5 stars	$145.61 -0.4%	$182.73 +25.5%	-16.7%	$40.30B	$21.84B	36.86	72,000	Positive News
DXCM DexCom	4.7595 of 5 stars	$74.22 -1.5%	$84.83 +14.3%	-13.7%	$29.08B	$4.66B	31.72	11,000	Positive News Analyst Forecast
RMD ResMed	4.9443 of 5 stars	$193.05 -0.9%	$279.82 +44.9%	-25.7%	$28.25B	$5.15B	18.62	10,600	Analyst Forecast
STE STERIS	4.9095 of 5 stars	$205.80 -0.9%	$278.00 +35.1%	-15.0%	$20.23B	$5.94B	25.95	17,937	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PODD) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Insulet (PODD) Competitors

PODD vs. BDX, DXCM, RMD, STE, and GMED

How does Insulet compare to Becton, Dickinson and Company?

Summary

How does Insulet compare to DexCom?

Summary

How does Insulet compare to ResMed?

Summary

How does Insulet compare to STERIS?

Summary

How does Insulet compare to Globus Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PODD vs. The Competition

Insulet Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Insulet (PODD) Competitors

PODD vs. BDX, DXCM, RMD, STE, and GMED

How does Insulet compare to Becton, Dickinson and Company?

Which has preferable earnings & valuation, BDX or PODD?

Does the media prefer BDX or PODD?

Which has more volatility and risk, BDX or PODD?

Is BDX or PODD more profitable?

Do insiders and institutionals believe in BDX or PODD?

Do analysts rate BDX or PODD?

Summary

How does Insulet compare to DexCom?

Does the media prefer DXCM or PODD?

Which has preferable valuation & earnings, DXCM or PODD?

Which has more risk and volatility, DXCM or PODD?

Do institutionals & insiders have more ownership in DXCM or PODD?

Do analysts prefer DXCM or PODD?

Is DXCM or PODD more profitable?

Summary

How does Insulet compare to ResMed?

Which has better earnings and valuation, RMD or PODD?

Do insiders & institutionals believe in RMD or PODD?

Is RMD or PODD more profitable?

Do analysts recommend RMD or PODD?

Which has more risk & volatility, RMD or PODD?

Does the media refer more to RMD or PODD?

Summary

How does Insulet compare to STERIS?

Do analysts prefer STE or PODD?

Is STE or PODD more profitable?

Do institutionals and insiders believe in STE or PODD?

Does the media refer more to STE or PODD?

Which has more risk & volatility, STE or PODD?

Which has higher earnings & valuation, STE or PODD?

Summary

How does Insulet compare to Globus Medical?

Does the media favor PODD or GMED?

Which has stronger earnings & valuation, PODD or GMED?

Do analysts rate PODD or GMED?

Do insiders & institutionals believe in PODD or GMED?

Is PODD or GMED more profitable?

Which has more risk and volatility, PODD or GMED?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PODD vs. The Competition

Insulet Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools